Beeline Reports Positive Phase 2 Results for Afimetoran

Stamford, Connecticut, U.S., November 11, 2026

Afimetoran Achieves Primary Endpoint Across All Three Doses

The global Phase 2 study evaluated the safety and efficacy of afimetoran in 248 adults with active moderate-to-severe systemic lupus erythematosus. Participants were randomly assigned to receive once-daily oral afimetoran at doses of 2.5 mg, 10 mg or 30 mg, or placebo, alongside permitted background standard-of-care treatments. The treatment period extended to 48 weeks, with researchers assessing disease activity and treatment responses. The primary endpoint measured the proportion of participants achieving an SLE Responder Index-4 (SRI-4) response at Week 48. All three afimetoran dose groups achieved statistically significant improvements compared with placebo. The SRI-4 response rates were 67.8% for the 2.5 mg dose, 64.1% for the 10 mg dose and 66.1% for the 30 mg dose, compared with 34.4% in the placebo group. The placebo-adjusted differences ranged from 30.2 to 31.5 percentage points, with p-values below 0.001 for all three doses. These findings indicate that afimetoran demonstrated consistent clinical activity across the evaluated dose levels. The results are particularly relevant because lupus is a complex autoimmune condition that can affect multiple organs, including the skin, joints, kidneys and cardiovascular system. Effective disease management requires therapies capable of controlling inflammation while reducing the long-term burden associated with the disease and its treatment.

Improvements in Skin, Joint Symptoms and Steroid Reduction

Beyond the primary endpoint, afimetoran demonstrated encouraging improvements across several important secondary clinical measures. At Week 48, response rates measured using the BILAG-based Composite Lupus Assessment (BICLA) ranged from 38.7% to 50.8% across the afimetoran groups, compared with 27.9% for placebo. The findings also showed improvements in the Lupus Low Disease Activity State (LLDAS), which was achieved by 35.6% to 39.1% of participants receiving afimetoran, compared with 21.3% in the placebo group. Another important finding involved corticosteroid reduction. Approximately 71.9% to 75.0% of afimetoran-treated participants reached or maintained a corticosteroid dose of 7.5 mg per day or less, compared with 50.0% of participants receiving placebo. Reducing long-term corticosteroid exposure is an important treatment objective in lupus because prolonged use can contribute to cumulative organ damage and other complications. The study also demonstrated improvements in skin and joint manifestations. Among participants with active skin disease at baseline, 57.1% to 66.7% of those receiving afimetoran achieved at least a 50% improvement in the Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score (CLASI-50), compared with 21.4% in the placebo group. Among participants with six or more active joints, 61.0% to 77.1% achieved at least a 50% reduction in active joint count, compared with 42.9% receiving placebo. Physician-reported assessments and patient-reported physical quality-of-life measurements also favored afimetoran, suggesting potential benefits across multiple aspects of disease management.

TLR7/8 Inhibition Supports Further Lupus Development

Afimetoran is an investigational selective oral inhibitor of Toll-like receptors 7 and 8 (TLR7/8), which play important roles in immune system activation and lupus disease development. These receptors contribute to inflammatory signaling and immune responses associated with autoimmune conditions. By blocking both pathways, afimetoran is designed to reduce abnormal immune activation involved in lupus progression. Exploratory biomarker analyses demonstrated rapid and sustained suppression of the type I interferon gene signature, an important biological pathway associated with lupus. The treatment also demonstrated improvements in disease-associated biomarkers, including reductions in anti-double-stranded DNA antibodies and increases in complement C3 and C4 levels toward the normal range among participants with abnormal baseline measurements. The safety findings were generally favorable over 48 weeks. Most treatment-emergent adverse events were mild to moderate, and no new safety signals were identified. Treatment-emergent adverse events occurred in 86.6% of participants receiving afimetoran compared with 79.0% receiving placebo. Severe treatment-emergent adverse events occurred in 3.2% of afimetoran-treated participants compared with 9.7% in the placebo group. Following the positive Phase 2 results, Beeline Medicines plans to advance afimetoran into Phase 3 development for systemic lupus erythematosus in 2027. The company has also initiated the global Phase 2/3 DISCOVERY trial to evaluate afimetoran in adults with cutaneous lupus erythematosus. The latest findings strengthen the clinical development programme and highlight the potential of targeted oral immunotherapies in autoimmune disease treatment. Although afimetoran remains investigational and is not approved for any use, further clinical evaluation will determine whether these promising results translate into meaningful and sustained benefits for people living with lupus.

Source: Beeline Medicines press release